An early Zoom investor was interested in another c
Post# of 25542
(Total Views: 162)
Posted On: 10/17/2022 8:17:04 AM
An early Zoom investor was interested in another company #RGC.
Regencell Bioscience Limited (NASDAQ:RGC) is a bioscience and healthcare company that focuses heavily on R&D and commercialization of Traditional Chinese Medicine (TCM) treatment, specifically ADHD (Attention Deficit Hyperactivity Disorder) and ASD (Autism Spectrum Disorders), as well as infectious diseases affecting people's immune systems such as COVID.
The stock price has increased by more than 300 percent since its IPO and saw a significant sell-off in mid-June, although it has recovered roughly 40% from its lows in June.
Of course, one of the greatest and strongest supporters of the business share is none other than the company) who believes in a better and brighter future for the firm.
In support of his dedication, belief, and position in the firm, the founder and CEO, (Mr Yat-Gai Au), has committed approximately $5 million dollars of his own reserves in purchasing back company shares to posture against probable short and distort sellers.
Mr Samuel Chen, a highly successful early **Zoom Video Communications, Inc.** investor, is another famous early RGC investor (Nasdaq: Zoom). Mr Samuel was the second largest individual investor, owning 8.8% of Zoom shares.
Mr. Au has so far converted his shareholders' loan of $3.25 million to Regencell's ordinary shares upon listing, vowed not to take more than $1 in pay and bonus until Regencell reaches a $1 billion market capitalization, and reserved share options for all workers except himself.
Furthermore, to demonstrate management's commitment to the firm, all directors and employees who were previously awarded stock options at Regencell's IPO have committed to a six-month lock-up period once their stock options become vested. Their shares will be locked up until January 16, 2023, since their stock options are slated to vest on July 16, 2022.
[https://www.benzinga.com/general/biotech/22/06/27567868/traders-may-keep-hunting-for-another-squeezable-stock-like-gamestop-how-does-this-tickers-short-i]
Regencell Bioscience Limited (NASDAQ:RGC) is a bioscience and healthcare company that focuses heavily on R&D and commercialization of Traditional Chinese Medicine (TCM) treatment, specifically ADHD (Attention Deficit Hyperactivity Disorder) and ASD (Autism Spectrum Disorders), as well as infectious diseases affecting people's immune systems such as COVID.
The stock price has increased by more than 300 percent since its IPO and saw a significant sell-off in mid-June, although it has recovered roughly 40% from its lows in June.
Of course, one of the greatest and strongest supporters of the business share is none other than the company) who believes in a better and brighter future for the firm.
In support of his dedication, belief, and position in the firm, the founder and CEO, (Mr Yat-Gai Au), has committed approximately $5 million dollars of his own reserves in purchasing back company shares to posture against probable short and distort sellers.
Mr Samuel Chen, a highly successful early **Zoom Video Communications, Inc.** investor, is another famous early RGC investor (Nasdaq: Zoom). Mr Samuel was the second largest individual investor, owning 8.8% of Zoom shares.
Mr. Au has so far converted his shareholders' loan of $3.25 million to Regencell's ordinary shares upon listing, vowed not to take more than $1 in pay and bonus until Regencell reaches a $1 billion market capitalization, and reserved share options for all workers except himself.
Furthermore, to demonstrate management's commitment to the firm, all directors and employees who were previously awarded stock options at Regencell's IPO have committed to a six-month lock-up period once their stock options become vested. Their shares will be locked up until January 16, 2023, since their stock options are slated to vest on July 16, 2022.
[https://www.benzinga.com/general/biotech/22/06/27567868/traders-may-keep-hunting-for-another-squeezable-stock-like-gamestop-how-does-this-tickers-short-i]
(0)
(0)